Condition: Carcinoma, Hepatocellular
Intervention:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Not yet recruiting
Feeds
4051 items (4051 unread) in 74 feeds
Acinar Cell Carcinoma
(27 unread)
Acinic Cell Carcinoma
(38 unread)
Adenoid Cystic Carcinoma
(58 unread)
Adrenal Gland Cancer
(291 unread)
Ampulla Of Vater
(25 unread)
Anal Cancer
(491 unread)
Angiosarcoma
(76 unread)
Appendix Cancer
(63 unread)
Bile Duct Cancer
(490 unread)
Brain and CNS
(587 unread)
Carcinoid
(83 unread)
Endocrine/Neuroendocrine
(497 unread)
Gall Bladder Cancer
(97 unread)
Hemangioendothelioma
(18 unread)
Hepatoblastoma
(35 unread)
Pancreas
(40 unread)
Phyllodes
(13 unread)
PMP and Mucinous Tumors
(15 unread)
Rhabdomyosarcoma
(99 unread)
Sarcoma
(1008 unread)
Trial - Cholangiocarcinoma (13 unread)
-
Prospective Surveillance for Very Early Hepatocellular Carcinoma
Posted: July 17th, 2018, 2:00pm GMT
-
EOC317 in Chinese Patients With Advanced Solid TumorsWith Advanced Solid Tumors
Posted: July 11th, 2018, 2:00pm GMT
Condition: Solid Tumor
Intervention: Drug: EOC317 Tablet
Sponsor: EddingPharm Oncology Co., LTD.
Recruiting -
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Not yet recruiting -
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
Posted: June 20th, 2018, 2:00pm GMT
Conditions: Breast Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Gastric Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Prostate Carcinoma
Interventions: Other: Interview; Other: Survey Administration
Sponsors: University of Southern California; National Cancer Institute (NCI)
Not yet recruiting -
Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients
Posted: May 17th, 2018, 2:00pm GMT
Conditions: Jaundice, Obstructive; Klatskin Tumor
Interventions: Procedure: PTBD group; Procedure: ENBD group; Procedure: EBS group
Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting -
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
Posted: May 10th, 2018, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: Apatinib
Sponsors: The First Affiliated Hospital of Zhengzhou University; Jiangsu HengRui Medicine Co., Ltd.
Recruiting -
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Posted: March 22nd, 2017, 2:00pm GMT
Conditions: Bile Duct Cancer; Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: Melphalan/HDS; Drug: Cisplatin and Gemcitabine
Sponsor: Delcath Systems Inc.
Recruiting -
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
Posted: December 12th, 2016, 3:00pm GMT
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: AG-120; Drug: AG-120 matched placebo
Sponsor: Agios Pharmaceuticals, Inc.
Recruiting -
Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy
Posted: October 5th, 2016, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: INCB054828
Sponsor: Incyte Corporation
Recruiting -
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Posted: July 4th, 2016, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Interventions: Biological: Durvalumab; Biological: Tremelimumab; Procedure: TACE; Procedure: RFA; Procedure: Cryoablation
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho
Posted: March 4th, 2016, 3:00pm GMT
Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting -
OLAParib COmbinations
Posted: October 15th, 2015, 2:00pm GMT
Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center; The Cleveland Clinic
Recruiting -
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
Posted: January 30th, 2015, 3:00pm GMT
Conditions: Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Ampullary Cancer
Interventions: Drug: Acelarin; Drug: Cisplatin
Sponsor: The Christie NHS Foundation Trust
Recruiting